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BACKGROUND
Daratumumab showed promising efficacy alone and with lenalidomide and dexametha-
sone in a phase 1–2 study involving patients with relapsed or refractory multiple myeloma.
METHODS
In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had 
received one or more previous lines of therapy to receive lenalidomide and dexamethasone 
either alone (control group) or in combination with daratumumab (daratumumab group). 
The primary end point was progression-free survival.
RESULTS
At a median follow-up of 13.5 months in a protocol-specified interim analysis, 169 events 
of disease progression or death were observed (in 53 of 286 patients [18.5%] in the dara-
tumumab group vs. 116 of 283 [41.0%] in the control group; hazard ratio, 0.37; 95% 
confidence interval [CI], 0.27 to 0.52; P<0.001 by stratified log-rank test). The Kaplan–
Meier rate of progression-free survival at 12 months was 83.2% (95% CI, 78.3 to 87.2) in 
the daratumumab group, as compared with 60.1% (95% CI, 54.0 to 65.7) in the control 
group. A significantly higher rate of overall response was observed in the daratumumab 
group than in the control group (92.9% vs. 76.4%, P<0.001), as was a higher rate of com-
plete response or better (43.1% vs. 19.2%, P<0.001). In the daratumumab group, 22.4% of 
the patients had results below the threshold for minimal residual disease (1 tumor cell 
per 105 white cells), as compared with 4.6% of those in the control group (P<0.001); results 
below the threshold for minimal residual disease were associated with improved out-
comes. The most common adverse events of grade 3 or 4 during treatment were neutro-
penia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the 
control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). 
Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and 
were mostly of grade 1 or 2.
CONCLUSIONS
The addition of daratumumab to lenalidomide and dexamethasone significantly length-
ened progression-free survival among patients with relapsed or refractory multiple my-
eloma. Daratumumab was associated with infusion-related reactions and a higher rate of 
neutropenia than the control therapy. (Funded by Janssen Research and Development; 
POLLUX ClinicalTrials.gov number, NCT02076009.)
a bs tr ac t
Daratumumab, Lenalidomide, and Dexamethasone  
for Multiple Myeloma
M.A. Dimopoulos, A. Oriol, H. Nahi, J. San‑Miguel, N.J. Bahlis, S.Z. Usmani, N. Rabin, R.Z. Orlowski, 
M. Komarnicki, K. Suzuki, T. Plesner, S.‑S. Yoon, D. Ben Yehuda, P.G. Richardson, H. Goldschmidt,  
D. Reece, S. Lisby, N.Z. Khokhar, L. O’Rourke, C. Chiu, X. Qin, M. Guckert, T. Ahmadi,  
and P. Moreau, for the POLLUX Investigators* 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV LIBRARY OF SOUTHERN DENMARK on September 8, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;14 nejm.org October 6, 20161320
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
The incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved 
outcomes in patients with multiple myeloma 
over the past 10 years,1-3 but most patients still 
eventually have a relapse.4 Relapse can occur 
even after standard complete remission in the 
context of first-line therapy, and studies are there-
fore evaluating deeper responses in a category 
termed “minimal residual disease–negative” 
(i.e., results below the threshold for minimal 
residual disease) that is prognostic with regard 
to a rate of disease progression in a time-to-
event analysis and overall survival.5,6 However, 
this category of minimal residual disease status 
has not been examined to date in patients with 
relapsed or refractory multiple myeloma, in part 
because of limited availability of data showing a 
correlation between depth of response and sur-
vival outcomes in patients at this stage of the 
disease.7
Daratumumab, a human IgGκ monoclonal 
antibody that targets CD38,8 has shown substan-
tial single-agent efficacy and a manageable safety 
profile in phase 1–2 studies involving patients 
with heavily pretreated relapsed or refractory 
multiple myeloma, with reported overall response 
rates of 29% and 36%.9,10 On the basis of these 
findings, daratumumab monotherapy (at a dose 
of 16 mg per kilogram of body weight) was ap-
proved by the Food and Drug Administration 
and the European Medicines Agency for these 
patients.11,12
The mechanisms of action of daratumumab 
comprise immune-mediated effects, including 
complement-dependent and antibody-dependent 
cell-mediated cytotoxic effects, antibody-depen-
dent cellular phagocytosis, and apoptosis by 
means of cross-linking.8,13-16 Moreover, daratumu-
mab may have a role in immunomodulation by 
means of depletion of CD38-positive regulator 
immune suppressor cells, which leads to a 
greater clonal expansion of T cells in patients 
who have a response than in those who do not.17
Daratumumab has shown efficacy in combi-
nation with standard-of-care therapies. A phase 3 
trial of bortezomib and dexamethasone, with or 
without daratumumab, met its primary end point 
at the interim analysis and showed a signifi-
cantly higher rate of progression-free survival, 
with a 61% lower risk of progression or death in 
the daratumumab group than in the control 
group.18 A phase 1–2 study of daratumumab, lena-
lidomide, and dexamethasone in patients with 
relapsed or refractory multiple myeloma showed 
that this combination provided therapeutic bene-
fits, no dose-limiting toxic effects, and an 81% 
rate of overall response, including a 25% rate of 
stringent complete response (a definition of this 
term is provided in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org).19 At 18 months, the rate of progres-
sion-free survival was 72%, and the rate of over-
all survival was 90%.19 Here we report the results 
of a prespecified interim analysis of a phase 3 
trial of daratumumab, lenalidomide, and dexa-
methasone in patients with relapsed or refrac-
tory multiple myeloma.
Me thods
Trial Design
In this randomized, open-label, multicenter, 
phase 3 trial, we assigned patients who had re-
lapsed or refractory multiple myeloma and had 
received one or more lines of previous therapy to 
receive either daratumumab, lenalidomide, and 
dexamethasone (daratumumab group) or lena-
lidomide and dexamethasone (control group). 
Patients underwent randomization between June 
16, 2014, and July 14, 2015, at 135 sites in 18 
countries across North America, Europe, and the 
Asia Pacific region. The trial was approved by 
the independent ethics committee or institutional 
review board at each site before the initiation of 
the trial. Patients provided written informed 
consent, and the trial was conducted in accor-
dance with the principles of the Declaration of 
Helsinki and current International Conference 
on Harmonisation Good Clinical Practice guide-
lines.
Patients
Patients had documented multiple myeloma and 
measurable disease at screening according to 
serum or urinary M-protein levels or serum free 
light-chain levels and abnormal serum immuno-
globulin free light-chain ratios (kappa:lambda 
light chains). Patients had progressive disease 
according to International Myeloma Working 
Group (IMWG) criteria (see the Supplementary 
Appendix) during or after the receipt of their last 
regimen, and they had received and had a re-
sponse to one or more lines of previous therapy. 
Key exclusion criteria were lenalidomide-refrac-
tory disease, the discontinuation of previous lena-
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lidomide treatment owing to adverse events, a 
neutrophil count of 1.0×109 or less per liter, 
a hemoglobin level of 7.5 g or less per deciliter, 
a platelet count of less than 75×109 per liter, an 
alanine aminotransferase or aspartate amino-
transferase level of 2.5 or more times the upper 
limit of the normal range, an alkaline phospha-
tase level of 2.5 or more times the upper limit of 
the normal range, a bilirubin level of 1.5 or more 
times the upper limit of the normal range, and 
a creatinine clearance of less than 30 ml per 
minute.
Treatments
Randomization (in a 1:1 ratio) was conducted by 
means of a central schedule and was balanced 
with the use of randomly permuted blocks and 
stratified according to the number of lines of 
previous therapy (1 vs. 2 or 3 vs. >3), Interna-
tional Staging System disease stage (I vs. II vs. 
III, with higher stages indicating more advanced 
disease; see the Supplementary Appendix) at 
screening, and previous receipt of lenalidomide 
(no vs. yes). Treatment cycles of 28 days contin-
ued until disease progression, an unacceptable 
level of toxic events, withdrawal of consent, or 
death.
For patients who were assigned to the daratu-
mumab group, daratumumab at a dose of 16 mg 
per kilogram was intravenously administered 
weekly (on days 1, 8, 15, and 22) for 8 weeks 
during cycles 1 and 2, every 2 weeks (on days 1 and 
15) for 16 weeks (cycles 3 through 6), and every 
4 weeks thereafter (Fig. S1 in the Supplementary 
Appendix). Both groups received lenalidomide at 
a dose of 25 mg orally on days 1 to 21 of each 
cycle if the creatinine clearance was more than 
60 ml per minute (or a dose of 10 mg daily if the 
creatinine clearance was 30 to 60 ml per minute) 
and dexamethasone at a dose of 40 mg weekly. 
For the daratumumab group, the dose of dexa-
methasone was split: dexamethasone was admin-
istered at a dose of 20 mg before infusion as 
prophylaxis for infusion-related reactions and 
20 mg was administered the next day. Patients 
in either group who were older than 75 years of 
age or whose body-mass index (the weight in 
kilograms divided by the square of the height in 
meters) was less than 18.5 received dexametha-
sone at a dose of 20 mg weekly at the discretion 
of their physician. The use of medications before 
and after infusion is summarized in the Supple-
mentary Appendix.
End Points and Assessments
The primary end point was progression-free sur-
vival, with progression determined with the use 
of a validated computer algorithm that combined 
laboratory results (e.g., M-protein level) and ap-
plicable imaging and generated the outcome ac-
cording to IMWG criteria (see the Supplementary 
Appendix).20,21 This algorithm previously showed 
very strong concordance with independent re-
views in a phase 2 study.9 Secondary end points 
included the time to disease progression in a 
time-to-event analysis, overall response rate, rate 
of very good partial response or better (compris-
ing very good partial, complete, and stringent 
complete responses), rate of complete response 
or better (comprising complete and stringent 
complete responses), percentages of patients 
with results below the threshold for minimal 
residual disease, time to response, duration of 
response, and overall survival. Disease assess-
ments (blood and 24-hour urinary values) were 
performed every 28 days (within a 3-day window 
before and after) by a central laboratory for 18 
months and every other cycle thereafter until 
progression.
Therapeutic monoclonal antibodies may inter-
fere with assessment of complete responses be-
cause a criterion requires negative immunofixa-
tion for monoclonal protein in the serum and 
urine.22 For patients with this suspected interfer-
ence from the treating antibody, a daratumumab-
specific immunofixation electrophoresis reflex 
assay was performed at the time of suspected 
complete response.23 Minimal residual disease 
status was evaluated by means of a next-genera-
tion sequencing assay of bone marrow obtained 
from patients who had a suspected complete 
response (see the Supplementary Appendix).
Safety assessments included evaluation of 
adverse events, clinical laboratory tests, electro-
cardiograms, vital signs, and physical exami-
nations. Follow-up was continued for patients 
who discontinued treatment. An independent 
data and safety monitoring committee was es-
tablished to periodically review unblinded safe-
ty data.
Trial Oversight
The investigators and the sponsor (Janssen Re-
search and Development) were responsible for 
the trial design and statistical analysis. Data were 
collected by the investigators and associated re-
search teams and were compiled and maintained 
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by the sponsor. All the investigators had access 
to the data on request and were not restricted by 
confidentiality agreements. Professional medical 
writers prepared the manuscript and were fund-
ed by the sponsor. All the authors reviewed, re-
vised, and approved the manuscript for submis-
sion. All the authors vouch for the accuracy and 
completeness of the data and for the adherence 
of the trial to the protocol (available, with the 
statistical analysis plan, at NEJM.org). Here we 
report results for the primary outcome and se-
lected secondary outcomes. Other secondary out-
comes are listed in the trial protocol. The results 
for those outcomes are compatible with the re-
sults presented here or have not yet been met.
Statistical Analysis
The group-sequential design had one planned 
interim analysis to evaluate the primary end 
point. We calculated that approximately 560 pa-
tients with 295 events (disease progression or 
death) would be needed to provide the trial with 
85% power to detect a 30% lower risk of disease 
progression or death (hazard ratio, 0.70), using 
a log-rank test, with an overall two-sided sig-
nificance level of 0.05. This interim analysis was 
to be conducted when approximately 177 events 
were observed (60% of the total expected events). 
For the primary end point, the O’Brien–Fleming 
stopping boundary at the interim analysis was 
calculated with the use of the Lan–DeMets alpha-
spending function on the basis of the numbers 
of observed events at the clinical cutoff date.24,25
If the primary end point was significant at 
the interim analysis, the major efficacy second-
ary end points of time to disease progression, 
rate of very good partial response, rate of results 
below the threshold for minimal residual dis-
ease, overall response rate, and overall survival, 
as ordered here, were sequentially tested, each 
with an overall two-sided alpha of 0.05. The 
population of patients whose response could be 
evaluated included patients who had measurable 
disease at baseline or the screening visit, had 
received at least one study treatment, and had 
undergone at least one disease assessment after 
the baseline visit; all the other efficacy analyses 
were based on the intention-to-treat population 
(patients who had undergone randomization). 
The safety population included all the patients 
who received at least one dose of trial treatment.
Progression-free survival was compared be-
tween groups on the basis of a stratified log-
rank test. The Kaplan–Meier method was used 
to estimate the distributions and 12-month rates 
of progression-free survival. Hazard ratios and 
95% confidence intervals were estimated with 
the use of a Cox regression model, with treat-
ment as the sole explanatory variable. Stratified 
Cochran–Mantel–Haenszel tests were used to 
compare overall response rates, rates of very 
good partial response or better, and other bi-
nary end points. Duration of response was as-
sessed by means of the Kaplan–Meier method.
R esult s
Patients and Treatment
Of 569 patients enrolled, 286 were assigned to 
the daratumumab group and 283 to the control 
group. The demographic and clinical character-
istics of the patients were well balanced at base-
line (Table 1, and Table S1 in the Supplementary 
Appendix). The median age of the patients was 
65 years (range, 34 to 89), and the median time 
since the initial diagnosis of multiple myeloma 
was 3.6 years.
Patients had received a median of 1 (range, 1 to 
11) previous line of therapy, and 19.2% of the 
patients had received 3 or more previous lines. 
Previous therapies included proteasome inhibi-
tors (in 85.6% of patients) and immunomodula-
tory drugs (in 55.2%), including lenalidomide (in 
17.6%), and 43.9% of the patients had received a 
proteasome inhibitor and immunomodulatory 
drug. A total of 63.3% of the patients had re-
ceived an autologous stem-cell transplant. A total 
of 27.4% of the patients had disease that was 
refractory to the last line of therapy.
At the clinical cutoff date on March 7, 2016, 
a total of 66 patients (23.3%) in the daratumu-
mab group and 132 (47.0%) in the control group 
had discontinued treatment. The most common 
reasons for the discontinuation of treatment 
were progressive disease (in 14.1% of the pa-
tients in the daratumumab group vs. 34.2% of 
those in the control group) and adverse events 
(in 6.7% vs. 8.2%) (Fig. S2 in the Supplementary 
Appendix). The median relative dose intensity of 
lenalidomide (the ratio of administered doses to 
planned doses) was 85.2% in the daratumumab 
group and 95.8% in the control group. The mean 
dose intensity of lenalidomide in patients who 
received trial treatment for at least 6 months was 
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Characteristic
Daratumumab Group 
(N = 286)
Control Group 
(N = 283)
Age
Median (range) — yr 65 (34–89) 65 (42–87)
Distribution — no. (%)
<65 yr 133 (46.5) 140 (49.5)
65 to 74 yr 124 (43.4) 108 (38.2)
≥75 yr 29 (10.1) 35 (12.4)
Race — no. (%)†
White 207 (72.4) 186 (65.7)
Black 5 (1.7) 11 (3.9)
Asian 54 (18.9) 46 (16.3)
Other or unreported 20 (7.0) 40 (14.1)
ECOG performance‑status score — no. (%)‡
0 139 (48.6) 150 (53.0)
1 or 2 147 (51.4) 133 (47.0)
ISS disease stage — no. (%)§
I 137 (47.9) 140 (49.5)
II 93 (32.5) 86 (30.4)
III 56 (19.6) 57 (20.1)
Cytogenetic profile — no./total no. (%)¶
Standard risk 193/228 (84.6) 176/211 (83.4)
High risk 35/228 (15.4) 35/211 (16.6)
Median time since diagnosis (range) — yr 3.5 (0.4–27.0) 4.0 (0.4–21.7)
Median no. of previous lines of therapy (range) 1 (1–11) 1 (1–8)
Previous therapy — no. (%)
Autologous stem‑cell transplant 180 (62.9) 180 (63.6)
Proteasome inhibitor 245 (85.7) 242 (85.5)
Immunomodulatory drug 158 (55.2) 156 (55.1)
Glucocorticoid 280 (97.9) 281 (99.3)
Alkylating agent 268 (93.7) 270 (95.4)
Proteasome inhibitor and immunomodulatory drug 125 (43.7) 125 (44.2)
Proteasome inhibitor, immunomodulatory drug,  
and alkylating agent
118 (41.3) 121 (42.8)
Bortezomib and lenalidomide 44 (15.4) 43 (15.2)
Refractory disease — no. (%)
To last line of therapy 80 (28.0) 76 (26.9)
To proteasome inhibitor only 57 (19.9) 46 (16.3)
To immunomodulatory drug only 10 (3.5) 11 (3.9)
To proteasome inhibitor and immunomodulatory drug 7 (2.4) 14 (4.9)
*  There were no significant differences between the two groups in the characteristics evaluated at baseline. The intention‑
to‑treat population was defined as all patients who underwent randomization.
†  Race was determined by the investigator.
‡  Eastern Cooperative Oncology Group (ECOG) performance status is scored on a scale from 0 to 5, with 0 indicating no 
symptoms and higher scores indicating increasing disability.
§  The International Staging System (ISS) disease stage is derived on the basis of the combination of serum β2‑
microglobulin and albumin levels. Higher stages indicate more advanced disease.
¶  Complete cytogenetic data were not available at the clinical cutoff date, and a prospective, centralized analysis of cyto‑
genetic data is ongoing.
Table 1. Demographic, Baseline Disease, and Clinical Characteristics in the Intention-to-Treat Population.*
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378 mg per cycle in the daratumumab group and 
429 mg per cycle in the control group.
Efficacy
At a median follow-up of 13.5 months, a total of 
169 events of disease progression or death (in 53 
patients [18.5%] in the daratumumab group vs. 
116 [41.0%] in the control group) were reported. 
The hazard ratio for disease progression or death 
in the daratumumab group versus the control 
group was 0.37 (95% confidence interval [CI], 
0.27 to 0.52; P<0.001 by stratified log-rank test), 
which crossed the prespecified stopping bound-
ary (Fig. 1). The Kaplan–Meier rate of progres-
sion-free survival at 12 months was 83.2% (95% 
CI, 78.3 to 87.2) in the daratumumab group and 
60.1% (95% CI, 54.0 to 65.7) in the control 
group. The median progression-free survival was 
not reached (95% CI, could not be estimated) in 
the daratumumab group, as compared with 18.4 
months (95% CI, 13.9 to could not be estimated) 
in the control group. Similarly, in the time-to-
event analysis of disease progression, a total of 
148 events (in 44 patients [15.4%] in the daratu-
mumab group vs. 104 [36.7%] in the control 
group) were observed (hazard ratio, 0.34; 95% 
CI, 0.23 to 0.48; P<0.001). The rate of progres-
sion-free survival at 12 months was 85.7% (95% 
CI, 80.9 to 89.4) in the daratumumab group, as 
compared with 63.2% (95% CI, 57.1 to 68.8) in 
the control group.
All the prespecified subgroup analyses of 
Figure 1. Progression-free Survival.
Shown are the results of the Kaplan–Meier analysis of progression‑free survival among patients in the intention‑to‑
treat population, which included all patients who underwent randomization. The P value is based on a stratified 
log‑rank test. The daratumumab group received daratumumab, lenalidomide, and dexamethasone, and the control 
group received lenalidomide and dexamethasone. NE denotes could not be estimated.
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progression-free survival confirmed the benefit 
of daratumumab (Fig. 2). Progression-free sur-
vival was significantly prolonged with the addi-
tion of daratumumab regardless of the number 
of previous lines of therapy (1 vs. a subgroup of 
1, 2, or 3) (Table S2 in the Supplementary Ap-
pendix). Progression-free survival was similarly 
prolonged in the daratumumab group among 
patients who had previous exposure to lenalido-
mide and those who had no previous exposure, 
as compared with the control group (Fig. S3 in 
the Supplementary Appendix).
The overall response rate in the population of 
patients who had a response that could be evalu-
ated was 92.9% in the daratumumab group ver-
sus 76.4% in the control group (P<0.001) (Table 2). 
Similar results were observed in the intention-
to-treat population (Table S3 in the Supplemen-
tary Appendix). The rate of very good partial 
response or better was significantly higher in 
Figure 2. Prespecified Subgroup Analyses.
Shown are the results of a prespecified subgroup analysis of progression‑free survival among patients with measur‑
able disease in serum in the intention‑to‑treat population. The daratumumab group received daratumumab, lenalido‑
mide, and dexamethasone, and the control group received lenalidomide and dexamethasone. The International Stag‑
ing System (ISS) disease stage is derived on the basis of the combination of serum β2‑microglobulin and albumin 
levels; higher stage indicates more advanced disease. The analysis of the subgroup of patients with disease that was 
refractory to a proteasome inhibitor was based on the subgroup of patients who received previous proteasome in‑
hibitor therapy. A total of 47 patients in the daratumumab group and 41 in the control group had a type of multiple 
myeloma not listed here.
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15/33
  24/133
  26/124
  3/29
  18/137
21/93
14/56
  27/149
16/85
  7/38
  3/14
10/50
  43/236
  48/245
  5/41
19/64
  29/181
23/80
  30/206
  16/151
13/49
13/39
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
Daratumumab
Group Hazard Ratio (95% CI)Subgroup
0.40 (0.24–0.67)
0.11 (0.02–0.51)
0.40 (0.23–0.72)
0.29 (0.17–0.50)
0.40 (0.21–0.76)
0.30 (0.17–0.52)
0.44 (0.22–0.89)
0.69 (0.30–1.57)
0.41 (0.26–0.66)
0.29 (0.16–0.53)
0.36 (0.13–1.03)
0.53 (0.10–2.87)
0.42 (0.19–0.90)
0.36 (0.25–0.52)
0.37 (0.26–0.52)
0.35 (0.12–1.00)
0.50 (0.27–0.93)
0.27 (0.17–0.43)
0.47 (0.27–0.80)
0.32 (0.20–0.49)
0.40 (0.24–0.65)
no. of progression
events or deaths/total no.
Control
Group
Daratumumab
Group
median progression-free
survival (mo)
0.1 1 10
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the daratumumab group than in the control 
group (75.8% vs. 44.2%, P<0.001), as was the 
rate of complete response or better (43.1% vs. 
19.2%, P<0.001). Consistent with the higher rates 
of deeper responses in the daratumumab group, 
the rate of results below the threshold for mini-
mal residual disease was significantly higher in 
the daratumumab group than in the control 
group (by 3 to 5 times) at all evaluated thresh-
olds (1 tumor cell per 104, 105, and 106 white 
cells) (Fig. S4 in the Supplementary Appendix). 
At a threshold of 1 tumor cell per 105 white cells, 
22.4% of patients in the daratumumab group 
had results below the threshold for minimal re-
sidual disease, as compared with 4.6% in the 
control group (P<0.001).
Several months of continuous therapy were 
required for complete response (Fig. S5 in the 
Supplementary Appendix). The median duration 
of response was not reached (95% CI, could not 
be estimated) in the daratumumab group, as 
compared with 17.4 months (95% CI, 17.4 to 
could not be estimated) in the control group.
Deeper responses resulted in longer progres-
sion-free survival. Among patients with a partial 
response or better, the rate of progression-free 
survival at 12 months was 87.8% (95% CI, 83.1 
to 91.3) in the daratumumab group versus 73.6% 
(95% CI, 67.0 to 79.1) in the control group. 
Among patients with very good partial response 
or better, the rate of progression-free survival 
was 91.7% (95% CI, 87.1 to 94.8) in the daratu-
mumab group versus 85.8% (95% CI, 78.1 to 
90.9) in the control group. Results below the 
threshold for minimal residual disease were as-
sociated with longer progression-free survival 
than results above the threshold (Fig. S6 in the 
Supplementary Appendix).
At the interim analysis, a total of 75 deaths 
had been observed (30 patients in the daratu-
mumab group and 45 in the control group) 
(Table S4 in the Supplementary Appendix). The 
Response Category
Daratumumab Group 
(N = 281)
Control Group 
(N = 276) P Value†
Overall response
No. with response 261 211 —
Rate — % (95% CI) 92.9 (89.2–95.6) 76.4 (71.0–81.3) <0.001
Clinical benefit — no. (%)‡ 266 (94.7) 237 (85.9) —
Best overall response — no. (%)
Complete response or better 121 (43.1) 53 (19.2) <0.001
Stringent complete response§ 51 (18.1) 20 (7.2) —
Complete response 70 (24.9) 33 (12.0) —
Very good partial response or better 213 (75.8) 122 (44.2) <0.001
Very good partial response 92 (32.7) 69 (25.0) —
Partial response 48 (17.1) 89 (32.2) —
Minimal response 5 (1.8) 26 (9.4) —
Stable disease 13 (4.6) 33 (12.0) —
Progressive disease 0 4 (1.4) —
Response could not be evaluated 2 (0.7) 2 (0.7) —
*  Response was assessed according to the Uniform Criteria Consensus recommendations of the International Myeloma 
Working Group.20,21 The analysis included patients who had a confirmed diagnosis of multiple myeloma and measurable 
disease at baseline or screening. In addition, patients had to have received at least one administration of trial treatment 
and must have had at least one disease assessment after the baseline visit.
†  P values were calculated with the use of the Cochran–Mantel–Haenszel chi‑square test.
‡  The category of clinical benefit includes all patients with a minimal response, partial response, very good partial response, 
complete response, and stringent complete response.
§  Criteria for a stringent complete response include the criteria for a complete response plus a normal free light‑chain ratio 
and the absence of clonal plasma cells as assessed by immunohistochemical or immunofluorescence analysis or by 
two‑color–to–four‑color flow cytometry.
Table 2. Summary of Responses among Patients with a Response That Could Be Evaluated.*
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Kaplan–Meier rate of overall survival at 12 
months was 92.1% (95% CI, 88.2 to 94.7) in the 
daratumumab group and 86.8% (95% CI, 82.2 to 
90.3) in the control group (Fig. S7 in the Supple-
mentary Appendix). Follow-up for long-term 
survival is ongoing.
Safety
The most common adverse events of any grade 
during treatment (in >15% of the patients in ei-
ther group) and adverse events of grade 3 or 4 
(in >5% of the patients in either group) for the 
safety population are summarized in Table 3. 
Adverse events that occurred at a frequency of 
10% or more in the daratumumab group versus 
the control group were neutropenia, diarrhea, 
upper respiratory tract infection, and cough, 
most of which resulted from longer exposure to 
treatment in the daratumumab group. Deep-vein 
thrombosis was reported in 1.8% of the patients 
in the daratumumab group and in 3.9% of those 
in the control group. In the daratumumab 
group, 51.9% of patients had neutropenia of 
grade 3 or 4, as compared with 37.0% of those 
in the control group; thrombocytopenia of grade 
3 or 4 occurred in 12.7% and 13.5% of the pa-
tients, respectively.
With regard to nonhematologic adverse events, 
Event
Daratumumab Group 
(N = 283)
Control Group 
(N = 281)
Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
Hematologic adverse event
Neutropenia 168 (59.4) 147 (51.9) 121 (43.1) 104 (37.0)
Anemia 88 (31.1) 35 (12.4) 98 (34.9) 55 (19.6)
Thrombocytopenia 76 (26.9) 36 (12.7) 77 (27.4) 38 (13.5)
Febrile neutropenia 16 (5.7) 16 (5.7) 7 (2.5) 7 (2.5)
Lymphopenia 17 (6.0) 15 (5.3) 15 (5.3) 10 (3.6)
Nonhematologic adverse event
Diarrhea 121 (42.8) 15 (5.3) 69 (24.6) 9 (3.2)
Fatigue 100 (35.3) 18 (6.4) 78 (27.8) 7 (2.5)
Upper respiratory tract infection 90 (31.8) 3 (1.1) 58 (20.6) 3 (1.1)
Constipation 83 (29.3) 3 (1.1) 71 (25.3) 2 (0.7)
Cough 82 (29.0) 0 35 (12.5) 0
Muscle spasms 73 (25.8) 2 (0.7) 52 (18.5) 5 (1.8)
Nasopharyngitis 68 (24.0) 0 43 (15.3) 0
Nausea 68 (24.0) 4 (1.4) 40 (14.2) 0
Pyrexia 57 (20.1) 5 (1.8) 31 (11.0) 4 (1.4)
Insomnia 55 (19.4) 1 (0.4) 55 (19.6) 2 (0.7)
Dyspnea 52 (18.4) 9 (3.2) 32 (11.4) 2 (0.7)
Back pain 50 (17.7) 4 (1.4) 48 (17.1) 4 (1.4)
Vomiting 47 (16.6) 3 (1.1) 15 (5.3) 2 (0.7)
Asthenia 45 (15.9) 8 (2.8) 36 (12.8) 7 (2.5)
Peripheral edema 43 (15.2) 2 (0.7) 37 (13.2) 3 (1.1)
Pneumonia 40 (14.1) 22 (7.8) 37 (13.2) 23 (8.2)
*  The safety population included all patients who received at least one dose of trial treatment. Adverse events of any 
grade that are listed are those that occurred in more than 15% of the patients in either group. Adverse events of grade 
3 or 4 that are listed are those that occurred in more than 5% of the patients in either group.
Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
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incidences of grade 3 or 4 diarrhea, fatigue, 
nausea, and dyspnea were slightly higher in the 
daratumumab group than in the control group. 
The rate of infection of grade 3 or 4 was also 
slightly higher in the daratumumab group than 
in the control group (28.3% and 22.8%, respec-
tively); the most common infection of grade 3 
or 4 was pneumonia, which occurred at similar 
rates in the two groups.
Serious adverse events were reported in 48.8% 
of the patients in the daratumumab group and 
in 42.0% of those in the control group, among 
which pneumonia was the most common (in 
8.1% of the patients in the daratumumab group 
and in 8.5% of those in the control group). Dara-
tumumab interferes with laboratory-based blood-
compatibility tests, including indirect Coombs’ 
test, because of binding to CD38 on red cells.26 
However, among patients who received blood 
transfusions, no hemolysis was observed.
The percentage of patients with adverse events 
leading to the discontinuation of treatment was 
similar in the two groups: 6.7% in the daratu-
mumab group and 7.8% in the control group. 
The most common adverse events (in ≥1% of the 
patients in either group) that led to the discon-
tinuation of treatment included pneumonia (in 
1.1% of the patients in the daratumumab group 
and in 0.7% of those in the control group), pul-
monary embolism (in 1.1% in the control group), 
and deterioration in general physical health (in 
1.1% in the daratumumab group). Adverse events 
leading to death occurred in 11 patients (3.9%) 
in the daratumumab group and in 15 (5.3%) in 
the control group. The most common adverse 
events leading to death were acute kidney injury 
(in 0.4% of the patients in the daratumumab 
group and in 1.1% in the control group), septic 
shock (in 1.1% and 0.4%, respectively), and 
pneumonia (in 0.7% in each group). Low rates of 
secondary primary cancer were reported in the 
two groups (in 2.8% of the patients in the dara-
tumumab group and in 3.6% of those in the 
control group); 10 of 18 patients (5 patients in 
each group) with secondary primary cancer had 
noninvasive, cutaneous secondary primary can-
cer such as squamous-cell carcinoma or basal-
cell carcinoma.
The incidence of daratumumab infusion- 
related reactions of any grade was 47.7%, with 
92% of the reactions occurring during the first 
infusion. These reactions were mostly of grade 1 
or 2; a total of 15 patients (5.3%) had grade 3 
infusion reactions, and no patient had an event 
of grade 4 or 5. The most common infusion-re-
lated reactions were cough (in 8.5% of the pa-
tients), dyspnea (in 8.5%), and vomiting (in 
5.7%) (Table S5 in the Supplementary Appendix). 
One patient discontinued daratumumab because 
of a grade 3 infusion-related event, recovered, 
and continued to receive lenalidomide and dexa-
methasone treatment.
Discussion
The results of this phase 3 trial show that the 
addition of daratumumab to lenalidomide and 
dexamethasone significantly prolonged progres-
sion-free survival and was associated with a 63% 
lower risk of disease progression or death than 
lenalidomide and dexamethasone alone among 
patients with multiple myeloma who had re-
ceived one or more lines of therapy previously. 
The treatment effect of daratumumab was con-
sistent regardless of previous exposure to lena-
lidomide (a limitation being the relatively small 
number of patients with previous exposure to 
lenalidomide) and across all subgroups, includ-
ing patients 65 years of age or older, those with 
disease that was refractory to proteasome in-
hibitors or the most recent line of therapy, those 
with International Staging System stage III dis-
ease, and those with previous exposure to a 
proteasome inhibitor or immunomodulatory drug. 
The treatment benefit that was associated with 
daratumumab was also similar in patients with 
one previous line of therapy and in those in a 
subgroup of patients with one, two, or three 
previous lines of therapy. Long-term follow-up is 
ongoing to assess differences in overall survival.
As in our trial (POLLUX), the addition of 
daratumumab to a standard-of-care regimen 
of bortezomib and dexamethasone in the CASTOR 
trial was associated with a significantly lower 
risk of disease progression or death.18 As in the 
CASTOR trial,18 the addition of daratumumab to 
the backbone regimen in our trial resulted in a 
significantly higher rate of overall response, 
deeper responses, and longer duration of re-
sponse. After continued treatment, responses 
deepened, with a rate of complete response or 
better that was twice as high with daratumumab 
as with the backbone regimen alone.
Patients who have very good partial responses 
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or better but have residual disease above recog-
nized thresholds have poorer outcomes than do 
those who are free from detectable residual dis-
ease, and subsequent studies have recognized 
that minimal residual disease status may serve 
as a surrogate for estimating disease control and 
survival.5,6 Although studies to date have focused 
on results below the threshold for minimal re-
sidual disease in patients with newly diagnosed 
disease (15% to 68% of patients across studies),5 
the patients with relapsed or refractory multiple 
myeloma in our trial had a rate of below-thresh-
old results that was more than four times as 
high in the daratumumab group as in the con-
trol group at the IMWG-recommended threshold 
of 1 tumor cell per 105 white cells for next-gener-
ation sequencing.5 Our findings were similar to 
findings in the context of first-line therapy5,6 in 
that results below the threshold for minimal 
residual disease were associated with prolonged 
progression-free survival among patients with 
relapsed or refractory multiple myeloma. This 
suggests that results below the threshold for 
minimal residual disease also should be a treat-
ment goal in the context of relapsed or refrac-
tory disease.
Cross-study comparisons should be interpret-
ed with caution because of differences in study 
design and eligibility criteria. However, other 
studies that have aimed to improve treatment in 
the context of salvage therapy have been pub-
lished. Two trials evaluated a proteasome in-
hibitor plus lenalidomide and dexamethasone 
versus lenalidomide and dexamethasone alone, 
with a hazard ratio for disease progression or 
death of 0.69 (median progression-free survival, 
26.3 vs. 17.6 months; overall response rate, 87% 
vs. 67%) with carfilzomib (in the ASPIRE [Carfil-
zomib, Lenalidomide, and Dexamethasone ver-
sus Lenalidomide and Dexamethasone for the 
Treatment of Patients with Relapsed Multiple 
Myeloma] trial)27 and a hazard ratio for disease 
progression or death of 0.74 (median progres-
sion-free survival, 20.6 vs. 14.7 months; overall 
response rate, 78% vs. 72%) with ixazomib (in the 
TOURMALINE-MM1 trial).28 The ELOQUENT-2 
trial of elotuzumab, a monoclonal antibody tar-
geting signaling lymphocytic activation molecule 
F7 (SLAMF7) that lacks single-agent activity, in 
combination with lenalidomide and dexametha-
sone as compared with lenalidomide and dexa-
methasone alone showed a hazard ratio for dis-
ease progression or death of 0.70 (median 
progression-free survival, 19.4 vs. 14.9 months; 
overall response rate, 79% vs. 66%).29,30
Daratumumab with lenalidomide and dexa-
methasone was associated with clinically man-
ageable adverse events that were consistent with 
the known toxic effects of lenalidomide and 
dexamethasone27,28,30,31 and of daratumumab.9,10 
Despite higher rates of neutropenia in the dara-
tumumab group, the rate of infection of grade 3 
or 4 was only slightly higher in the daratumu-
mab group than in the control group (28% vs. 
23%). The rates of treatment discontinuation 
owing to adverse events were low and similar 
in the two groups. After the implementation of 
guidelines from other studies of daratumumab 
regarding the management of infusion-related 
reactions, infusion-related reactions were con-
sistent with daratumumab monotherapy9,10 and 
combination therapy,18,19,32 were mostly of grade 
1 or 2, and usually occurred during the first 
infusion.
In conclusion, daratumumab with lenalido-
mide and dexamethasone was associated with a 
significant progression-free survival benefit and 
higher rates of overall response and results be-
low the threshold for minimal residual disease 
than lenalidomide and dexamethasone alone 
among patients with relapsed or refractory mul-
tiple myeloma. Although higher rates of neutro-
penia and infusion-related reactions (primarily 
during the first infusion) were observed with 
this combination than with lenalidomide and 
dexamethasone alone, these events did not result 
in higher rates of treatment discontinuation or 
death.
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